FOXP3 and diabetes mellitus: Administration of hybrid insulin peptide-coupled PLG NPs was found to prevent diabetes by impairing the ability of CD4+ T cells to produce proinflammatory cytokines through induction of anergy, leading to an increase in the ratio of Foxp3+ regulatory T cells to IFN-γ+ effector T cells.